A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
Tohnya
Tanyifor M
TM
Clinical Pharmacology Research Core, National Institutes of Health, Bethesda, MD, USA.
Ng
Sylvia S W
SS
Dahut
William L
WL
Wright
John J
JJ
Arlen
Philip M
PM
Gulley
James L
JL
Parker
Catherine
C
Zeldis
Jerome
J
Figg
William D
WD
D000284:Administration, Oral; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D009362:Neoplasm Metastasis; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012107:Research Design; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D013792:Thalidomide; D000077269:Lenalidomide